NXN 188

Drug Profile

NXN 188

Alternative Names: NXN-188

Latest Information Update: 24 Jun 2015

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator NeurAxon
  • Class Small molecules
  • Mechanism of Action Calcitonin gene-related peptide antagonists; Nitric oxide synthase inhibitors; Serotonin receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Migraine

Most Recent Events

  • 08 Jun 2015 Phase-II development of an oral formulation of NXN 188 is ongoing in the US, Canada and Denmark
  • 01 Jan 2015 NXN 188 licensed to Knight Therapeutics in Canada, Israel, South Africa and Russia
  • 31 Aug 2012 Preclinical study pharmacodynamics data in Migraine presented at the 14th World Congress on Pain (WCP-2012)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top